Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome

ClinicalTrials.gov ID: NCT03790865

Public ClinicalTrials.gov record NCT03790865. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analogue, on Food-related Behaviors in Patients With Prader-Willi Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 2b/3 double-blind, placebo-controlled study will evaluate the safety, tolerability, and effects of livoletide on food-related behaviors in patients with Prader-Willi Syndrome (PWS).

Study identification

NCT ID: NCT03790865
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Millendo Therapeutics SAS; Industry
Enrollment: 158 participants

Conditions and interventions

Conditions

Interventions

Livoletide Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 4 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 25, 2019 (Actual)
Primary completion: Feb 26, 2020 (Actual)
Completion: May 25, 2020 (Actual)
Last update posted: Feb 17, 2021

2019 – 2020

United States locations

U.S. sites: 15
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35233	—
University of California - Irvine Medical Center	Orange	California	92868	—
Rady Children's Hospital - San Diego	San Diego	California	92123	—
Children's Hospital Colorado	Denver	Colorado	80045	—
University of Kansas Medical Center	Kansas City	Kansas	66160	—
Johns Hopkins University	Baltimore	Maryland	21287	—
Boston Children's Hospital	Boston	Massachusetts	02215	—
University of Michigan	Ann Arbor	Michigan	48109	—
Children's Hospitals and Clinics of Minnesota-Minneapolis	Saint Paul	Minnesota	55102	—
Winthrop University Hospital	Mineola	New York	11501	—
New York Presbyterian Morgan Stanley Children's Hospital	New York	New York	10032	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—
Baylor College of Medicine	Houston	Texas	77030	—
Seattle Children's Hospital	Seattle	Washington	98105	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03790865, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 17, 2021 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03790865 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →